ARLG Scientific Agenda
The ARLG has prioritized four areas of research and is soliciting clinical studies to:
Infections caused by Gram-negative bacteria
- Develop and test antimicrobial agents or strategies for Gram-negative infections in adults or children caused by multiple-drug resistance gram-negative bacilli including carbapenem-resistant, expanded-spectrum cephalosporin-resistant, or quinolone-resistant bacteria.
- Evaluate novel agents or strategies to prevent emergence of resistance during treatment of infections caused by Gram-negative bacilli.
- Optimize administration of antimicrobial agents for treatment of Gram-negative infections with respect to dose, dosing interval, and duration of therapy in adults or children.
Infections caused by Gram-positive bacteria.
- Investigate strategies or therapies, including narrow-spectrum oral antimicrobials, for treatment of infections predominantly caused by Gram-positive bacteria, including skin and soft tissue infections, bone and joint infections, and bacteremia in adults and children.
- Compare the effectiveness of linezolid and daptomycin or other antibiotics alone or in combination with other agents for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) or vancomycin resistant enterococci (VRE).
- Optimize administration of antimicrobial agents for treatment of Gram-positive infections with respect to dose, dosing interval, and duration of therapy in adults or children.
- Assess antibacterial stewardship strategies for non-use or early discontinuation of antibacterial therapy to reduce emergence and spread of antibiotic resistant bacteria.
- Evaluate transmission dynamics or emergence of carbapenem-resistant, expanded-spectrum cephalosporin-resistant, or quinolone-resistant Gram-negative bacilli in healthcare and community settings.
- Examine strategies (e.g., stewardship, decolonization, probiotics) to prevent occurrence or recurrence or reduce the risk of resistant Gram-negatives, Clostridium difficile infection, VRE, or MRSA.
- Evaluate methods or platforms, which may include biomarkers or host-response markers (e.g., “omics”) to rapidly identify bacterial pathogens and infections. Approaches could include simple and rapid point-of-care diagnostics to detect drug resistance, guide antibacterial therapy, or support clinical trials.
- Evaluate rapid, accurate methods for antimicrobial susceptibility testing of cultured bacteria.
If you would like to submit a proposal for a research study, please complete the ARLG Concept Proposal Survey.